Matches in Nanopublications for { ?s ?p "[Overexpression of PPARdelta or activation of PPARdelta by its pharmacological ligand, GW501516, at low doses (0.5-50 nM) promoted the growth of three human cholangiocarcinoma cell lines (CCLP1, HuCCT1, and SG231).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine."@en ?g. }
Showing items 1 to 2 of
2
with 100 items per page.
- NP568838.RAKDc6u0gofbCv2W5k_ryO9QXqYA68jwF3B-Cxrqp8Gbc130_assertion description "[Overexpression of PPARdelta or activation of PPARdelta by its pharmacological ligand, GW501516, at low doses (0.5-50 nM) promoted the growth of three human cholangiocarcinoma cell lines (CCLP1, HuCCT1, and SG231).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP568838.RAKDc6u0gofbCv2W5k_ryO9QXqYA68jwF3B-Cxrqp8Gbc130_provenance.
- NP797101.RAyw5YOIevL_HgIPsTSGxQUsxMAVLxJiOPVyDlq1nsLs4130_assertion description "[Overexpression of PPARdelta or activation of PPARdelta by its pharmacological ligand, GW501516, at low doses (0.5-50 nM) promoted the growth of three human cholangiocarcinoma cell lines (CCLP1, HuCCT1, and SG231).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP797101.RAyw5YOIevL_HgIPsTSGxQUsxMAVLxJiOPVyDlq1nsLs4130_provenance.